APF530

granisetron extended-release formulation · Heron Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for APF530, covering 2016-12-28 to 2026-02-12. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin